MEI Pharma Inc
NASDAQ:MEIP
| Market Cap (Intraday) | 323.56M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.85 |
| 50-Day MA | $2.81 |
| 200-Day MA | $3.13 |
MEI Pharma Inc Stock, NASDAQ:MEIP
11455 El Camino Real, Suite 250, San Diego, California 92130
United States of America
Phone: +1.858.369.7100
Number of Employees: 76
Description
MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.